Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignancies
Гуманизация каркасных областей повышает эффективность нанотельных CAR-T-клеток против CD72 при B-клеточных злокачественных новообразованиях
2023-11-01
SCID: 54.1/zfw4vvbv
Discuss with AI
B-cell malignanciesCD72 antigen downregulationCD72 nanoCAR-T cellsaffinity maturationframework humanization
Figures from the paper
Abstract (AI)
Background Approximately 50% of patients who receive anti-CD19 CAR-T cells relapse, and new immunotherapeutic targets are urgently needed. We recently described CD72 as a promising target in B-cell malignancies and developed nanobody-based CAR-T cells (nanoCARs) against it. This cellular therapy design is understudied compared with scFv-based CAR-T cells, but has recently become of significant interest given the first regulatory approval of a nanoCAR in multiple myeloma. Methods We humanized our previous nanobody framework regions, derived from llama, to generate a series of humanized anti-CD72 nanobodies. These nanobody binders were inserted into second-generation CD72 CAR-T cells and were evaluated against preclinical models of B cell acute lymphoblastic leukemia and B cell non-Hodgkin’s lymphoma in vitro and in vivo. Humanized CD72 nanoCARs were compared with parental (“NbD4”) CD72 nanoCARs and the clinically approved CD19-directed CAR-T construct tisangenlecleucel. RNA-sequencing, flow cytometry, and cytokine secretion profiling were used to determine differences between the different CAR constructs. We then used affinity maturation on the parental NbD4 construct to generate high affinity binders against CD72 to test if higher affinity to CD72 improved antitumor potency. Results Toward clinical translation, here we humanize our previous nanobody framework regions, derived from llama, and surprisingly discover a clone (“H24”) with enhanced potency against B-cell tumors, including patient-derived samples after CD19 CAR-T relapse. Potentially underpinning improved potency, H24 has moderately higher binding affinity to CD72 compared with a fully llama framework. However, further affinity maturation (KD<1 nM) did not lead to improvement in cytotoxicity. After treatment with H24 nanoCARs, in vivo relapse was accompanied by CD72 antigen downregulation which was partially reversible. The H24 nanobody clone was found to have no off-target binding and is therefore designated as a true clinical candidate. Conclusion This work supports translation of H24 CD72 nanoCARs for refractory B-cell malignancies, reveals potential mechanisms of resistance, and unexpectedly demonstrates that nanoCAR potency can be improved by framework alterations alone. These findings may have implications for future engineering of nanobody-based cellular therapies.
Key Findings
1
Further affinity maturation to subnanomolar affinity (KD<1 nM) did not improve nanoCAR cytotoxicity, indicating that higher affinity alone is insufficient to enhance activity.
2
H24 displayed moderately higher CD72-binding affinity than the parental fully llama framework, potentially contributing to its improved potency.
3
H24 nanoCAR-T cells were effective against B-cell acute lymphoblastic leukemia and non-Hodgkin lymphoma models, including patient-derived samples from CD19 CAR-T relapse.
4
Humanizing llama-derived anti-CD72 nanobody frameworks generated the H24 clone, which showed enhanced anti-tumor potency against B-cell malignancies.
5
Relapse after H24 nanoCAR treatment was associated with CD72 antigen downregulation that was partially reversible; H24 showed no off-target binding in the reported evaluation.
Research Object
humanized anti-CD72 nanobody-based CAR-T cells targeting B-cell malignancies
Research Subject
the effects of nanobody framework humanization and CD72-binding affinity on CAR-T cytotoxicity, antitumor potency, antigen escape, and off-target binding
Publication Details
Publication Date
2023-11-01
Journal
Publisher
ISSN
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest